Sort
48,018 grants matching “immunotherapy”
The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
$631,075Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2021 · CA
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors
$631,007Andras A. Heczey · Baylor College Of Medicine · R01 · FY2025 · CA
Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence
$630,987Jeffrey N Bruce · Columbia University Health Sciences · R01 · FY2024 · NS
A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria
$630,959Molly A Hughes · University Of Virginia · R01 · FY2021 · AI
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
$630,957Hongjun Wang · Medical University Of South Carolina · R01 · FY2021 · DK
Heterlogous Prime and Boost Vaccine Strategies
$630,946Jonathan Smith · Duke University · P01 · FY2008 · CA
Development of quantitative optical tools to continuously monitor cerebral autoregulation, blood flow, oxygenation and inflammation during pediatric extracorporeal life support
$630,796David Richard Busch · Ut Southwestern Medical Center · R01 · FY2025 · NS
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
$630,790Jennifer D Wu · Northwestern University At Chicago · R01 · FY2024 · CA
Engineered Lipid Nanoparticles and Microgel Matrix to Program Th1/Th2 Immune Response
$630,781Hai-Quan Mao · Johns Hopkins University · R01 · FY2025 · CA
IGF::OT::IGF RATIONAL DESIGN AND DEVELOPMENT OF A MULTI-ANTIGEN, MULTI-PEPTIDE VACCINE BASED ON GENOMIC INFORMATION TO PREVENT LUNG CANCER INITIATION AND PROGRESSIONHHSN2612015000371
$630,760Ming You · Medical College Of Wisconsin · N01 · FY2016 · CA
IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma
$630,729Ekaterina Koltsova · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$630,691Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2023 · CA
Alloreactive and autoreactive immune-mediated mechanisms of impaired epithelial regeneration in the GI tract
$630,679Alan M Hanash · Sloan-Kettering Inst Can Research · R01 · FY2018 · HL
Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma
$630,665Giannicola Genovese · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
MS4A7 in tumor resistance to immunotherapy
$630,650Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
$630,641Katherine W Ferrara · Stanford University · R01 · FY2019 · CA
Immune Enhancement and Therapy of Cancer
$630,621University Of California San Francisco · U01 · FY2005 · CA
Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies
$630,619Richard J Simpson · University Of Arizona · R01 · FY2023 · CA
(PQ1) Lipid Metabolism, Inflammation, and T cell Dysfunction in HIV-associated Cancer
$630,537Brinda Emu · Yale University · R01 · FY2021 · CA
Development of Immunologic therapies against uveitis
$630,535Charles E Egwuagu · National Eye Institute · ZIA · FY2024 · EY
Strategies to Reduce Global Health Disparities in Cervical Cancer
$630,506T.-C. Wu · Johns Hopkins University · R01 · FY2025 · CA
Development of simpler immunotheraputics
$630,497Arya Biragyn · National Institute On Aging · ZIA · FY2021 · AG
Targeting polo-like kinase for therapy of small cell lung cancer
$630,466Taofeek K Owonikoko · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers
$630,459Kathrin Milbury · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk
$630,457Saikrishna Yendamuri · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA